scholarly journals Neural Stem Cells: A Dual Functional Scaffold Tethered with EGFR Antibody Promotes Neural Stem Cell Retention and Neuronal Differentiation for Spinal Cord Injury Repair (Adv. Healthcare Mater. 9/2017)

2017 ◽  
Vol 6 (9) ◽  
Author(s):  
Bai Xu ◽  
Yannan Zhao ◽  
Zhifeng Xiao ◽  
Bin Wang ◽  
Hui Liang ◽  
...  
Stem Cells ◽  
2021 ◽  
Vol 39 (8) ◽  
pp. 1025-1032 ◽  
Author(s):  
Weiwei Xue ◽  
Caixia Fan ◽  
Bing Chen ◽  
Yannan Zhao ◽  
Zhifeng Xiao ◽  
...  

2005 ◽  
Vol 27 (8) ◽  
pp. 812-819 ◽  
Author(s):  
Hajime Kimura ◽  
Masahide Yoshikawa ◽  
Ryousuke Matsuda ◽  
Hayato Toriumi ◽  
Fumihiko Nishimura ◽  
...  

2016 ◽  
Vol 26 (32) ◽  
pp. 5835-5847 ◽  
Author(s):  
Xing Li ◽  
Sumei Liu ◽  
Yannan Zhao ◽  
Jiayin Li ◽  
Wenyong Ding ◽  
...  

2021 ◽  
Vol 2 (2) ◽  
pp. 519-537
Author(s):  
Mallesh Kurakula ◽  
Shashank Gorityala ◽  
Devang B. Patel ◽  
Pratap Basim ◽  
Bhaumik Patel ◽  
...  

Spinal cord injury (SCI) is one of the most complicated nervous system injuries with challenging treatment and recovery. Regenerative biomaterials such as chitosan are being reported for their wide use in filling the cavities, deliver curative drugs, and also provide adsorption sites for transplanted stem cells. Biomaterial scaffolds utilizing chitosan have shown certain therapeutic effects on spinal cord injury repair with some limitations. Chitosan-based delivery in stem cell transplantation is another strategy that has shown decent success. Stem cells can be directed to differentiate into neurons or glia in vitro. Stem cell-based therapy, biopolymer chitosan delivery strategies, and scaffold-based therapeutic strategies have been advancing as a combinatorial approach for spinal cord injury repair. In this review, we summarize the recent progress in the treatment strategies of SCI due to the use of bioactivity of chitosan-based drug delivery systems. An emphasis on the role of chitosan in neural regeneration has also been highlighted.


2019 ◽  
Vol 41 (1-2) ◽  
pp. 79-93 ◽  
Author(s):  
Shen Li ◽  
Jiao Zheng ◽  
Linlin Chai ◽  
Mengsi Lin ◽  
Ruocheng Zeng ◽  
...  

Oligodendrocyte progenitor cells (OPCs) may have beneficial effects in cell replacement therapy of neurodegenerative disease owing to their unique capability to differentiate into myelinogenic oligodendrocytes (OLs) in response to extrinsic signals. Therefore, it is of significance to establish an effective differentiation methodology to generate highly pure OPCs and OLs from some easily accessible stem cell sources. To achieve this goal, in this study, we present a rapid and efficient protocol for oligodendroglial lineage differentiation from mouse neural stem cells (NSCs), rat NSCs, or mouse embryonic stem cell-derived neuroepithelial stem cells. In a defined culture medium containing Smoothened Agonist, basic fibroblast growth factor, and platelet-derived growth factor-AA, OPCs could be generated from the above stem cells over a time course of 4–6 days, achieving a cell purity as high as ∼90%. In particular, these derived OPCs showed high expandability and could further differentiate into myelin basic protein-positive OLs within 3 days or alternatively into glial fibrillary acidic protein-positive astrocytes within 7 days. Furthermore, transplantation of rodent NSC-derived OPCs into injured spinal cord indicated that it is a feasible strategy to treat spinal cord injury. Our results suggest a differentiation strategy for robust production of OPCs and OLs from rodent stem cells, which could provide an abundant OPC source for spinal cord injury.


2018 ◽  
Vol 6 (2) ◽  
pp. 265-271 ◽  
Author(s):  
Xing Li ◽  
Jianwu Dai

Severe spinal cord injury (SCI) induces massive proliferation of spinal cord neural stem cells (NSCs), which are considered a promising cell source for therapeutic neural repair.


Sign in / Sign up

Export Citation Format

Share Document